Roivant Sciences Ltd.

ROIV

BMG762791017

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
11.13 ^USD	+0.91%		+5.00%	-0.89%

Apr. 05	Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit	MT
Apr. 04	Moderna Suffers Setback in Lawsuit by Arbutus	MT

Roivant Sciences Ltd.(NasdaqGS:ROIV) added to S&P 400 Health Care

April 31, 2024

Roivant Sciences Ltd.(NasdaqGS:ROIV) added to S&P 400 Health Care (Sector)

Latest news about Roivant Sciences Ltd.

Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit	Apr. 05	MT
Moderna Suffers Setback in Lawsuit by Arbutus	Apr. 04	MT
Moderna shares fall after judge sides with Arbutus in patent fight	Apr. 03	RE
Deutsche Bank Raises Roivant Sciences' Price Target to $15 From $14, Maintains Buy Rating	Apr. 03	MT
Goldman Sachs Raises Roivant Sciences' Price Target to $18 From $16, Maintains Buy Rating	Apr. 03	MT
HC Wainwright Raises Roivant Sciences Price Target to $18 From $17, Maintains Buy Rating	Apr. 03	MT
Roivant Sciences Says Study of Potential Uveitis Treatment Meets Endpoints; Launches Stock Repurchase; Shares Rise	Apr. 02	MT
Transcript : Roivant Sciences Ltd. - Special Call	Apr. 02
Roivant Sciences Ltd. announces an Equity Buyback for $1,500 million worth of its shares.	Apr. 02	CI
Roivant's anti-inflammatory drug succeeds in mid-stage study	Apr. 02	RE
Roivant and Priovant Therapeutics Announce Positive Results from the Phase 2 Study for Brepocitinib in NIU	Apr. 02	CI
Roivant Sciences Ltd. authorizes a Buyback Plan.	Apr. 01	CI
Roivant Sciences Ltd.(NasdaqGS:ROIV) added to S&P 1000	Mar. 31	CI
Roivant Sciences Ltd.(NasdaqGS:ROIV) added to S&P 400 - Biotechnology	Mar. 31	CI
Roivant Sciences Ltd.(NasdaqGS:ROIV) added to S&P 400 Health Care	Mar. 31	CI
Roivant Sciences Ltd.(NasdaqGS:ROIV) added to S&P Composite 1500	Mar. 31	CI
Roivant Sciences Ltd.(NasdaqGS:ROIV) added to S&P 400	Mar. 31	CI
Sunrun, Roivant Shares Rise Ahead of Inclusion in S&P SmallCap, MidCap Indexes	Mar. 27	MT
Transcript : Roivant Sciences Ltd. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 01:20 PM	Mar. 11
Wolfe Research Initiates Roivant Sciences With Outperform Rating, $17 Price Target	Feb. 15	MT
Roivant Sciences Swings to Fiscal Q3 Earnings as Net Revenue Rises	Feb. 13	MT
Transcript : Roivant Sciences Ltd., Q3 2024 Earnings Call, Feb 13, 2024	Feb. 13
Roivant Sciences Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 13	CI
Stocks Decline Pre-Bell Ahead of Key Inflation Data; Asia Mixed, Europe Down	Feb. 13	MT
Roivant Sciences Insider Sold Shares Worth $1,058,694, According to a Recent SEC Filing	Feb. 12	MT

Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company that seeks to improve the lives of patients by accelerating the development and commercialization of medicines that matter. The Companyâs pipeline is focused on inflammation and immunology and includes VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; batoclimab and IMVT-1402, fully human monoclonal antibodies targeting the neonatal Fc receptor (FcRn) in development across several IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody in development for ulcerative colitis and Crohnâs disease, in addition to various other therapies in various stages of clinical development. The Company advances its pipeline by creating nimble subsidiaries or Vants to develop and commercialize its medicines and technologies. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.

Sector

Pharmaceuticals

Calendar

2024-06-25 - Q4 2023 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Roivant Sciences Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.13 USD

Average target price

16.08 USD

Spread / Average Target

+44.47%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ROIVANT SCIENCES LTD.	-0.89%	8.97B
ELI LILLY AND COMPANY	+26.47%	664B
NOVO NORDISK A/S	+26.74%	567B
JOHNSON & JOHNSON	-6.33%	354B
MERCK & CO., INC.	+19.35%	330B
ABBVIE INC.	+4.23%	286B
ASTRAZENECA PLC	+13.43%	234B
NOVARTIS AG	+4.71%	199B
ROCHE HOLDING AG	-9.53%	196B
AMGEN INC.	-4.04%	148B

Other Pharmaceuticals